All tumors expressed at least one glial marker (GFAP 10/10, S100 4/4, OLIG2 8/8) with variable positivity in neuronal markers, Moreover, the activation of the mTOR pathway was present to a greater extent than in other NF1-associated gliomas, a finding that was supported by prior reports and may provide novel therapeutic approaches (Table 2) [80,81]. This evidence concerns the gene NF1 and glioma.